Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Molecular Targeting Technologies Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The presence of only 1 pending office action suggests a targeted prosecution strategy. Because all current activity is confined to 1 distinct art unit, the company's immediate patenting efforts are focused on a specific technical niche within the pharmaceutical field.
The busiest examiner for the company is JONES, DAMERON LEVEST, who is managing 1 busiest examiner pending action. As there is only 1 pending office action in the entire portfolio, JONES, DAMERON LEVEST is the sole official currently reviewing the company's applications. The lack of examiner and art unit diversity means that the company's success depends on navigating the specific preferences of this 1 distinct examiner. This concentrated workload allows for a focused legal strategy tailored to the requirements of the 1 distinct art unit involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041532 | COMPOUNDS AND COMPOSITIONS FOR TUMOR DETECTION AND SURGICAL GUIDANCE | JONES, DAMERON LEVEST | 43d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18041532 | COMPOUNDS AND COMPOSITIONS FOR TUMOR DETECTION AND SURGICAL GUIDANCE | JONES, DAMERON LEVEST | 1618 | §103 | Final Rejection | 43d overdue | Pending | Feb 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial